Cutaneous squamous cell carcinoma: A review with consideration of special patient groups;Kutanes plattenepithelkarzinom unter berücksichtigung besonderer patientengruppen

Hautarzt

Volumn 65, Issue 7, 2014, Pages 590-599

  Hillen, U ^a   Ulrich, M ^b,h   Alter, M ^c   Becker, J C ^d   Gutzmer, R ^d   Leiter, U ^e   Lonsdorf, A ^f   Messerschmidt, A ^g   Ulrich, C ^h  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Dermatologie am Regierungsviertel   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Distant metastases; Immunosuppression; Lymph node metastasis; Non melanoma skin cancer; Therapy

Indexed keywords

CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; DISTANT METASTASIS; GERIATRIC DISORDER; HUMAN; LIFE EXPECTANCY; LYMPH NODE METASTASIS; REVIEW; SKIN CARCINOMA; SURVIVAL RATE; AGE DISTRIBUTION; CARCINOMA, SQUAMOUS CELL; INCIDENCE; MORTALITY; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SKIN NEOPLASMS; SKIN SURGERY;

ANTINEOPLASTIC AGENT;

AGE DISTRIBUTION; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DERMATOLOGIC SURGICAL PROCEDURES; HUMANS; INCIDENCE; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84905079865     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-013-2734-7     Document Type: Review

References (55)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic review of worldwide incidence of non-melanoma skin cancer. Br J Dermatol 166: 1069-1080
2. Katalinic A, Kunze U, Schafer T (2003) Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 149:1200-1206 (Pubitemid 38058096)
3. Alam M, Ratner D (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344:975-983 (Pubitemid 32240317)
4. Hollestein LM, Vries E de, Nijsten T (2012) Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989-2008. Eur J Cancer 48:2046-2053
5. Kraywinkel K, Wolf U, Katalinic A (2012) Hautkrebs - Epidemiologie und Früherkennung. UMID, Umwelt und Mensch-Informationsdienst. Ausgabe 2:30-34
6. Elmets CA, Athar M (2013) Milestones in photocarcinogenesis. J Invest Dermatol 133:E13-E17
7. Schwarz T (2010) The dark and the sunny sides of UVR-induced immunosuppression: photoimmunology revisited. J Invest Dermatol 130:49-54
8. Nakazawa H, English D, Randell PL et al (1994) UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci U S A 91:360-364 (Pubitemid 24018704)
9. Ratushny V, Gober MD, Hick R et al (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122:464-472
10. Griewank KG, Murali R, Schilling B et al (2013) TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One 8:e80354
11. Bundeministerium für Arbeit und Soziales (2013) Empfehlung des Ärztlichen Sachverständigenbeirats "Berufskrankheiten". Gem Ministerialbl 64: 671-693
12. Rangwala S, Tsai KY (2011) Roles of the immune system in skin cancer. Br J Dermatol 165:953-965
13. Mehrany K, Weenig RH, Lee KK et al (2005) Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol 53: 1067-1071 (Pubitemid 41677335)
14. Lott DG, Manz R, Koch C, Lorenz RR (2010) Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 90: 683-687
15. Weedon D, Marks R, Kao GF, Harwood CA (2006) Keratinocytic tumors. In: LeBoit PE, Burg G, Weedon D, Sarasin A (Hrsg) World health organization classification of tumours. IARC Press, Lyon
16. Farasat S, Yu SS, Neel VA et al (2011) A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 64:1051-1059
17. Karia PS, Jambusaria-Pahlajani A, Harrington DP et al (2014) Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 32:327-334
18. Breuninger H, Brantsch K, Eigentler T, Hafner HM (2012) Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges 10:579-586
19. Brantsch KD, Meisner C, Schonfisch B et al (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9:713-720
20. Schmults CD, Karia PS, Carter JB et al (2013) Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 149:541-547
21. Wittekind C, Meyer H (Hrsg) (2010) TNM Klassifikation maligner Tumore. Wiley-VCH, Weinheim
22. Clayman GL, Lee JJ, Holsinger FC et al (2005) Mortality risk from squamous cell skin cancer. J Clin Oncol 23:759-765 (Pubitemid 46237442)
23. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4:905-913 (Pubitemid 38745589)
24. Na R, Grulich AE, Meagher NS et al (2013) Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. Am J Transplant 13:174-183
25. Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65:263-279 (quiz 280)
26. Wisgerhof HC, Edelbroek JR, Fijter JW de et al (2010) Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 89:1231-1238
27. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348: 1681-1691 (Pubitemid 36459475)
28. Greene MH, Hoover RN, Fraumeni JF Jr (1978) Subsequent cancer in patients with chronic lymphocytic leukemia - a possible immunologic mechanism. J Natl Cancer Inst 61:337-340 (Pubitemid 9019566)
29. Beiggi S, Johnston JB, Seftel MD et al (2013) Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 109:1287-1290
30. Mehrany K, Weenig RH, Pittelkow MR et al (2005) High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia. Dermatol Surg 31:38-42 (discussion 42)
31. Royle JA, Baade PD, Joske D et al (2011) Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 105:1076-1081
32. Long MD, Martin CF, Pipkin CA et al (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143:390-399
33. Setshedi M, Epstein D, Winter TA et al (2012) Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 27:385-389
34. Singh H, Nugent Z, Demers AA, Bernstein CN (2011) Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 141:1612-1620
35. Pedersen N, Duricova D, Elkjaer M et al (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 105:1480-1487
36. Curtis JR, Jain A, Askling J et al (2010) A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 40:2-14
37. Mercer LK, Green AC, Galloway JB et al (2012) The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71:869-874
38. Stern RS, PUVA Follow-up Study (2012) The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 66:553-562
39. Pouplard C, Brenaut E, Horreau C et al (2013) Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 27(Suppl 3):36-46
40. Brewer JD, Hoverson Schott AR, Roenigk RK (2011) Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature. Int J Dermatol 50:1555-1559
41. Young L, Czarnecki D (2012) The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 53:57-60
42. Di Lernia V, Ricci C (2011) Cutaneous malignancies during treatment with efalizumab and infliximab: when temporal relationship does not mean causality. J Dermatolog Treat 22:229-232
43. Breuninger H, Eigentler T, Bootz F et al (2013) Brief S2k guidelines - cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 11:37-45, 39-47
44. Bonerandi JJ, Beauvillain C, Caquant L et al (2011) Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol 25(Suppl 5):1-51
45. National Comprehensive Cancer Network (2014) Basal cell and squamous cell skin cancers. NCCN clinical practice guidelines in oncology. http://www.nccn.org
46. Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP (1997) Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer 79:915-919 (Pubitemid 27089874)
47. Sadek H, Azli N, Wendling JL et al (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66:1692-1696 (Pubitemid 20381201)
48. Grau JJ, Caballero M, Verger E et al (2009) Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 129:1294-1299
49. Hitt R, Irigoyen A, Cortes-Funes H et al (2012) Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23:1016-1022
50. Maubec E, Petrow P, Scheer-Senyarich I et al (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419-3426
51. Lewis CM, Glisson BS, Feng L et al (2012) A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18:1435-1446
52. Mecca C, Ponzetti A, Caliendo V et al (2012) Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 22:758-761
53. Gutierrez-Dalmau A, Revuelta I, Ferrer B et al (2010) Distinct immunohistochemical phenotype of nonmelanoma skin cancers between renal transplant and immunocompetent populations. Transplantation 90:986-992
54. Euvrard S, Morelon E, Rostaing L et al (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329-339
55. Hillen U, Griewank K, Sommerwerck U et al (2013) Tumor regression and sirolimus-based therapy in lung transplantation. J Heart Lung Transplant 32:938-939